PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pacira BioSciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$36.34+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.46B
- P/E (TTM)
- 103.8
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
44M of 40M shares
Institutional holders
253
38 new, 24 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 16 sales
Net sold $2.53M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,017,119 | 15.20% | 13G (passive) amendment | Mar 31, 2025 |
| Joe M. Thomson | 3,262,837 | 6.93% | 13G (passive) | Dec 31, 2024 |
| Pedro Escudero | 2,936,794 | 7.30% | 13D (active) amendment | Mar 11, 2026 |
| Doma Perpetual Capital Management LLC | 2,936,794 | 6.83% | 13D (active) amendment | Nov 6, 2025 |
| Vanguard Portfolio Management | 2,585,964 | 6.38% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 2,088,291 | 5.15% | 13G (passive) | Mar 31, 2026 |
| Dimensional Fund Advisors LP | 2,060,597 | 5.10% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 2,059,977 | 5.20% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PCRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,705,809 | 16.82% | $170.13M | −29,534 | 0.00% |
| Doma Perpetual Capital Management LLC | 2,777,794 | 6.97% | $70.47M | – | 16.36% |
| Vanguard Portfolio Management LLC | 2,406,238 | 6.04% | $61.05M | −95,048 | 0.00% |
| Dimensional Fund Advisors LP | 2,103,245 | 5.28% | $53.36M | +42,648 | 0.01% |
| State Street Corp | 2,059,977 | 5.17% | $52.26M | +140,367 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,950,332 | 4.89% | $49.48M | −32,392 | 0.02% |
| Renaissance Technologies LLC | 1,733,801 | 4.35% | $43.99M | −91,700 | 0.06% |
| Vanguard Capital Management LLC | 1,691,571 | 4.24% | $42.92M | −92,478 | 0.00% |
| Goldman Sachs Group Inc | 1,527,129 | 3.83% | $38.74M | −42,787 | 0.00% |
| Geode Capital Management, LLC | 1,158,693 | 2.91% | $29.40M | +14,873 | 0.00% |
| Morgan Stanley | 1,144,654 | 2.87% | $29.04M | −247,894 | 0.00% |
| American Century Companies Inc | 1,018,093 | 2.55% | $25.83M | +180,530 | 0.01% |
| UBS Group AG | 920,217 | 2.31% | $23.35M | +358,177 | 0.00% |
| Impax Asset Management Group plc | 750,027 | 1.88% | $19.03M | – | 0.12% |
| Two Sigma Investments, LP | 724,604 | 1.82% | $18.38M | +197,753 | 0.01% |
| Charles Schwab Investment Management Inc | 690,786 | 1.73% | $17.53M | −41,256 | 0.00% |
| Gagnon Securities LLC | 608,617 | 1.53% | $15.44M | −8,893 | 2.98% |
| Lsv Asset Management | 608,376 | 1.53% | $15.43K | +91,276 | 0.03% |
| Wellington Management Group Llp | 563,458 | 1.41% | $14.29M | +85,075 | 0.00% |
| Northern Trust Corp | 526,782 | 1.32% | $13.36M | +7,370 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 253 | 44M | 100.0% | 38 / 82 | 84 / 24 | 3M | 3M |
| Q1 2026 | 242 | 44M | 100.0% | 29 / 90 | 85 / 43 | 7M | 6M |
| Q4 2025 | 261 | 47M | 100.0% | 49 / 87 | 92 / 24 | 5M | 6M |
| Q3 2025 | 239 | 48M | 100.0% | 37 / 66 | 96 / 30 | 5M | 7M |
| Q2 2025 | 233 | 51M | 100.0% | 31 / 84 | 77 / 32 | 6M | 6M |
| Q1 2025 | 235 | 51M | 100.0% | 35 / 84 | 77 / 31 | 10M | 9M |
| Q4 2024 | 233 | 50M | 100.0% | 36 / 77 | 80 / 40 | 8M | 10M |
| Q3 2024 | 239 | 52M | 100.0% | 47 / 88 | 68 / 88 | 24M | 16M |
| Q2 2024 | 282 | 53M | 100.0% | 51 / 106 | 76 / 38 | 8M | 6M |
| Q1 2024 | 271 | 51M | 100.0% | 38 / 99 | 83 / 28 | 6M | 4M |
| Q4 2023 | 261 | 49M | 100.0% | 41 / 88 | 91 / 38 | 7M | 5M |
| Q3 2023 | 261 | 47M | 100.0% | 41 / 96 | 87 / 38 | 5M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PCRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2,371,127 | 5.95% | $60.16M | 0.05% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,198,792 | 3.01% | $30.41M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,033,788 | 2.59% | $26.23M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 856,213 | 2.15% | $21.72M | 0.01% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 762,506 | 1.91% | $17.71M | 0.07% | May 31, 2026 |
| Impax Small Cap Fund | 750,027 | 1.88% | $19.03M | 2.00% | Jun 30, 2026 |
| U.S. Small Cap Value Portfolio | 570,177 | 1.43% | $15.06M | 0.08% | Jul 31, 2026 |
| Vanguard Small-Cap Value Index Fund | 542,876 | 1.36% | $13.77M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 453,754 | 1.14% | $11.51M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 432,505 | 1.09% | $11.42M | 0.03% | Jul 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 360,632 | 0.90% | $9.15M | 0.05% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 351,941 | 0.88% | $8.93M | 0.11% | Jun 30, 2026 |
| DWS Small Cap Core Fund | 349,906 | 0.88% | $8.88M | 0.77% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 340,170 | 0.85% | $8.63M | 0.06% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 279,152 | 0.70% | $7.08M | 1.65% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Frank D. Lee | Chief Executive Officer, Director | 660,831 | 1.66% | Feb 13, 2026 |
| Jonathan Slonin | Chief Medical Officer | 216,384 | 0.54% | Aug 18, 2026 |
| Lauren Riker | Senior Vice President, Finance | 62,284 | 0.16% | Jun 12, 2026 |
| Kristen Williams | Chief Administrative Officer | 167,062 | 0.42% | Jun 5, 2026 |
| Shawn Cross | Chief Financial Officer | 105,341 | 0.26% | Apr 24, 2026 |
| Brendan Teehan | Chief Commercial Officer | 100,934 | 0.25% | Feb 13, 2026 |
| Daryl Gaugler | Chief Operating Officer | 115,443 | 0.29% | Jan 6, 2025 |
| Marcelo Bigal | Director | 17,798 | 0.04% | Jun 12, 2026 |
| Michael J. Yang | Director | 19,798 | 0.05% | Jun 12, 2026 |
| Thomas G. Wiggans | Director | – | – | Jun 12, 2026 |
| Laura Brege | Director | 30,120 | 0.08% | Jun 12, 2026 |
| Mark Froimson | Director | 26,541 | 0.07% | Jun 12, 2026 |
| Christopher Christie | Director | 23,059 | 0.06% | Jun 12, 2026 |
| Samit Hirawat | Director | 6,405 | 0.02% | Jun 12, 2026 |
| Alethia Young | Director | 17,798 | 0.04% | Jun 12, 2026 |
| Mark A. Kronenfeld | Director | 31,065 | 0.08% | Mar 19, 2026 |
| Abraham Ceesay | Director | 9,039 | 0.02% | Sep 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jonathan Slonin Chief Medical Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −3,040 | $23.23 | $70.62K | 216,384 |
| Lauren Riker Senior Vice President, Finance | Jun 11, 2026 | Sale(10b5-1 plan) | −6,115 | $23.50 | $143.70K | 62,284 |
| Christopher Christie Director | Jun 10, 2026 | Award | +6,405 | – | – | 23,059 |
| Michael J. Yang Director | Jun 10, 2026 | Award | +6,405 | – | – | 19,798 |
| Samit Hirawat Director | Jun 10, 2026 | Award | +6,405 | – | – | 6,405 |
| Laura Brege Director | Jun 10, 2026 | Award | +6,405 | – | – | 30,120 |
| Alethia Young Director | Jun 10, 2026 | Award | +6,405 | – | – | 17,798 |
| Mark Froimson Director | Jun 10, 2026 | Award | +6,405 | – | – | 26,541 |
| Marcelo Bigal Director | Jun 10, 2026 | Award | +6,405 | – | – | 17,798 |
| Kristen Williams Chief Administrative Officer | Jun 4, 2026 | Sale(10b5-1 plan) | −10,259 | $22.27 | $228.47K | 167,062 |
| Kristen Williams Chief Administrative Officer | Jun 3, 2026 | Tax withholding | −8,528 | $22.32 | $190.34K | 177,321 |
| Jonathan Slonin Chief Medical Officer | Jun 3, 2026 | Tax withholding | −4,728 | $22.32 | $105.53K | 218,912 |
| Lauren Riker Senior Vice President, Finance | Jun 3, 2026 | Tax withholding | −3,187 | $22.32 | $71.13K | 68,399 |
| Shawn Cross Chief Financial Officer | Apr 23, 2026 | Sale(10b5-1 plan) | −12,941 | $25.16 | $325.60K | 105,341 |
| Shawn Cross Chief Financial Officer | Apr 23, 2026 | Option exercise | +12,941 | $16.45 | $212.88K | 118,282 |
| Shawn Cross Chief Financial Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −1,500 | $25.01 | $37.52K | 105,341 |
| Shawn Cross Chief Financial Officer | Apr 22, 2026 | Option exercise | +1,500 | $16.45 | $24.68K | 106,841 |
| Shawn Cross Chief Financial Officer | Apr 21, 2026 | Sale(10b5-1 plan) | −2,845 | $25.01 | $71.15K | 105,341 |
| Shawn Cross Chief Financial Officer | Apr 21, 2026 | Option exercise | +2,845 | $16.45 | $46.80K | 108,186 |
| Shawn Cross Chief Financial Officer | Apr 20, 2026 | Option exercise | +7,714 | $16.45 | $126.90K | 113,055 |
| Shawn Cross Chief Financial Officer | Apr 20, 2026 | Sale(10b5-1 plan) | −7,714 | $25.14 | $193.93K | 105,341 |
| Mark Froimson Director | Mar 17, 2026 | Sale | −500 | $21.81 | $10.91K | 20,136 |
| Jonathan Slonin Chief Medical Officer | Mar 17, 2026 | Sale(10b5-1 plan) | −3,261 | $22.82 | $74.42K | 223,640 |
| Shawn Cross Chief Financial Officer | Feb 11, 2026 | Award | +49,091 | – | – | 105,341 |
| Jonathan Slonin Chief Medical Officer | Feb 11, 2026 | Award | +54,546 | – | – | 226,901 |
| Brendan Teehan Chief Commercial Officer | Feb 11, 2026 | Award | +51,714 | – | – | 100,934 |
| Frank D. Lee Chief Executive Officer, Director | Feb 11, 2026 | Award | +261,818 | – | – | 660,831 |
| Kristen Williams Chief Administrative Officer | Feb 11, 2026 | Award | +54,546 | – | – | 185,849 |
| Lauren Riker Senior Vice President, Finance | Feb 11, 2026 | Award | +19,273 | – | – | 71,586 |
| Kristen Williams Chief Administrative Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −13,137 | $20.53 | $269.70K | 131,303 |
| Lauren Riker Senior Vice President, Finance | Feb 2, 2026 | Sale(10b5-1 plan) | −4,000 | $20.81 | $83.24K | 52,313 |
| Kristen Williams Chief Administrative Officer | Jan 30, 2026 | Tax withholding | −17,134 | $20.54 | $351.93K | 144,440 |
| Frank D. Lee Chief Executive Officer, Director | Jan 30, 2026 | Tax withholding | −41,488 | $20.54 | $852.16K | 399,013 |
| Lauren Riker Senior Vice President, Finance | Jan 30, 2026 | Tax withholding | −2,751 | $20.54 | $56.51K | 56,313 |
| Jonathan Slonin Chief Medical Officer | Jan 30, 2026 | Tax withholding | −6,168 | $20.54 | $126.69K | 172,355 |
| Brendan Teehan Chief Commercial Officer | Jan 30, 2026 | Tax withholding | −5,182 | $20.54 | $106.44K | 49,220 |
| Lauren Riker Senior Vice President, Finance | Jan 5, 2026 | Sale(10b5-1 plan) | −1,416 | $24.24 | $34.32K | 59,064 |
| Jonathan Slonin Chief Medical Officer | Jan 2, 2026 | Tax withholding | −381 | $24.46 | $9.32K | 178,523 |
| Frank D. Lee Chief Executive Officer, Director | Jan 2, 2026 | Tax withholding | −9,272 | $24.46 | $226.79K | 440,501 |
| Lauren Riker Senior Vice President, Finance | Jan 2, 2026 | Tax withholding | −159 | $24.46 | $3.89K | 60,480 |
| Brendan Teehan Chief Commercial Officer | Dec 31, 2025 | Award | +402.27 | $10.76 | $4.33K | 54,402 |
| Shawn Cross Chief Financial Officer | Dec 10, 2025 | Sale(10b5-1 plan) | −9,104 | $25.14 | $228.87K | 56,250 |
| Shawn Cross Chief Financial Officer | Dec 10, 2025 | Option exercise | +9,104 | $16.45 | $149.76K | 65,354 |
| Shawn Cross Chief Financial Officer | Dec 9, 2025 | Sale(10b5-1 plan) | −15,896 | $25.03 | $397.88K | 56,250 |
| Shawn Cross Chief Financial Officer | Dec 9, 2025 | Option exercise | +15,896 | $16.45 | $261.49K | 72,146 |
| Jonathan Slonin Chief Medical Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −3,960 | $24.09 | $95.40K | 178,367 |
| Shawn Cross Chief Financial Officer | Nov 10, 2025 | Sale(10b5-1 plan) | −12,060 | $22.09 | $266.41K | 56,250 |
| Shawn Cross Chief Financial Officer | Oct 31, 2025 | Tax withholding | −6,690 | $21.38 | $143.03K | 68,310 |
| Abraham Ceesay Director | Sep 4, 2025 | Sale(10b5-1 plan) | −2,354 | $27.19 | $64.01K | 9,039 |
| Marcelo Bigal Director | Aug 7, 2025 | Sale | −4,912 | $23.67 | $116.27K | 11,393 |
| Jonathan Slonin Chief Medical Officer | Aug 1, 2025 | Tax withholding | −315 | $22.07 | $6.95K | 182,327 |
| Mark A. Kronenfeld Director | Jun 11, 2025 | Award | +6,163 | – | – | 31,065 |
| Marcelo Bigal Director | Jun 11, 2025 | Award | +6,163 | – | – | 16,305 |
| Mark A. Kronenfeld Director | Jun 11, 2025 | Award | +9,999 | – | – | 34,901 |
| Mark Froimson Director | Jun 11, 2025 | Award | +6,163 | – | – | 20,636 |
| Abraham Ceesay Director | Jun 11, 2025 | Award | +6,163 | – | – | 11,393 |
| Christopher Christie Director | Jun 11, 2025 | Award | +6,163 | – | – | 16,654 |
| Michael J. Yang Director | Jun 11, 2025 | Award | +6,163 | – | – | 13,393 |
| Laura Brege Director | Jun 11, 2025 | Award | +6,163 | – | – | 23,715 |
| Alethia Young Director | Jun 11, 2025 | Award | +6,163 | – | – | 11,393 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lauren Riker Officer | Oct 8, 2026 | 6,000 | $217.92K | Oct 8, 2026 | Stock Option Exercise |
| Jonathan Slonin Officer | Aug 17, 2026 | 3,040 | $70.62K | Aug 17, 2026 | ESPP Purchase |
| Abraham Ceesay Director | Jun 12, 2026 | 9,039 | $210.37K | Jun 12, 2026 | Restricted Stock Vesting |
| Lauren Riker Officer | Jun 11, 2026 | 6,115 | $143.70K | Jun 11, 2026 | Restricted Stock Vesting |
| Kristen Williams Officer | Jun 4, 2026 | 10,259 | $228.47K | Jun 4, 2026 | Restricted Stock Vesting |
| Shawn Cross Officer | Apr 23, 2026 | 12,941 | $325.58K | Apr 23, 2026 | Options Granted - 11/04/2024 |
| Shawn Cross Officer | Apr 22, 2026 | 1,500 | $37.52K | Apr 22, 2026 | Option Granted - 11/04/2024 |
| Shawn Cross Officer | Apr 21, 2026 | 2,845 | $71.15K | Apr 21, 2026 | Option Granted - 11/04/2024 |
| Shawn Cross Officer | Apr 20, 2026 | 7,714 | $193.91K | Apr 20, 2026 | Option Granted 11/04/2024 |
| Jonathan Slonin Officer | Mar 17, 2026 | 3,261 | $74.42K | Mar 17, 2026 | ESPP Purchase |
| Mark Froimson Director | Mar 17, 2026 | 500 | $10.91K | Mar 17, 2026 | Restricted Stock Vesting |
| Kristen Williams Officer | Feb 2, 2026 | 13,137 | $269.70K | Feb 2, 2026 | Restricted Stock Vesting |
| Lauren Riker Officer | Feb 2, 2026 | 4,000 | $84.22K | Feb 2, 2026 | Restricted Stock Vesting |
| Lauren Riker Officer | Jan 5, 2026 | 1,416 | $34.32K | Jan 5, 2026 | ESPP Purchase |
| Shawn Cross Officer | Dec 10, 2025 | 9,104 | $228.91K | Dec 10, 2025 | Option Granted 11/04/2024 |